Neuroleptic malignant syndrome: a dangerous complication of neuroleptic therapy.
Neuroleptic malignant syndrome is a potentially fatal syndrome that can occur in patients taking neuroleptics or other psychotropic drugs. It is characterized by muscle rigidity, hyperthermia, altered mentation, autonomic dysfunction, increased CPK and leukocytosis. A primary factor in NMS may be a decrease in functioning of dopaminergic neurons. Treatment usually consists of discontinuation of the neuroleptic drug, drug therapy with bromocriptine and dantrolene and supportive measures. The key to successful medical and nursing management is aggressive supportive care with a focus on preventing complications. With the frequency of administration of neuroleptic drugs, neuroscience nurses should be aware of this potentially lethal complication of neuroleptic therapy.
Byrd
C
C
St. Francis Medical Center, Cape Girardeau, Missouri 63701.
D000328:Adult; D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use; D003620:Dantrolene / Q000494:pharmacology / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000451:nursing / Q000628:therapy
D001971:Bromocriptine; D003620:Dantrolene